GlassScriptPhysician profile
Aret Y Kahyaoglu
NPI 1811023682
$5,048.94
in general payments reported to CMS, 2019-2025
33 companies · $421 in 2025
The $421 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $1,181 · 2021: $1,113 · 2022: $621 · 2023: $681 · 2024: $270 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.85 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $560.90 | 2021-2025 | |
| Novo Nordisk INC | $415.48 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Pfizer INC. | $394.43 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.49 | 2019-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $311.17 | 2019-2022 | |
| Amgen INC. | $212.88 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $205.53 | 2019-2025 | Breztri |
| Allergan, INC. | $197.44 | 2019-2020 | |
| Glaxosmithkline, LLC. | $189.72 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $187.61 | 2019-2020 | |
| Astellas Pharma US INC | $185.99 | 2021-2024 | Veozah |
| Arbor Pharmaceuticals, INC. | $147.38 | 2020-2022 | |
| Esperion Therapeutics, INC. | $138.06 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $120.71 | 2023-2025 | Edarbi, Edarbi, Horizant |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $109.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $97.73 | 2019-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $88.38 | 2021-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $83.20 | 2019-2021 | |
| Almatica Pharma LLC | $68.96 | 2021-2023 | Gralise, Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $51.45 | 2019-2025 | Zoryve |
| Althera Pharmaceuticals LLC | $48.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.15 | 2022-2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $32.25 | 2023 | Gvoke Hypopen |
| Jazz Pharmaceuticals INC. | $28.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.48 | 2023 | |
| Renalytix Ai, INC. | $20.17 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Seqirus USA INC | $17.56 | 2025 | Flucelvax, Fluad |
| Lexicon Pharmaceuticals, INC. | $16.34 | 2023 | Inpefa |
| Biohaven Pharmaceutical Holding Company LTD. | $15.42 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.79 | 2021 | |
| Genentech USA, INC. | $13.26 | 2020 | |
| Alexion Pharmaceuticals, INC. | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aret Kahyaoglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.